WAM
PSTV icon

Warberg Asset Management’s Plus Therapeutics PSTV Stock Holding History

Warberg Asset Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27
Closed -$3.17K – 276
2022
Q4 		$3.17K Hold
27
– – ﹤0.01% 242
2022
Q3 		$5K Sell
27
-40
-60% -$8.93K ﹤0.01% 262
2022
Q2 		$14K Buy
+67
New +$16.7K ﹤0.01% 193

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GVAG
Great Valley Advisor Group Wilmington, Delaware $5.5B AUM 20.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Warberg Asset Management's PSTV Position: Q1 2023 in Review

Warberg Asset Management sold out of Plus Therapeutics (PSTV) in Q1 2023, closing a stake of 27 shares — an estimated $3.17K sold.

Warberg Asset Management first reported a position in PSTV in Q2 2022 and held it in 3 quarters. The position peaked at $14K in Q2 2022. 16 funds tracked by Wall St. Rank hold PSTV as of Q1 2023.

  • Warberg Asset Management reported no remaining Plus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Warberg Asset Management sold 27 Plus Therapeutics shares in Q1 2023, an estimated $3.17K.
  • Warberg Asset Management first reported a position in Plus Therapeutics in Q2 2022 and held it in 3 quarters.
  • Warberg Asset Management's Plus Therapeutics position peaked at $14K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2023.

Based on Warberg Asset Management's 13F filing for Q1 2023, filed 15 May 2023.